Lunai Bioworks (NASDAQ:LNAI) Cut to Sell at Wall Street Zen

Lunai Bioworks (NASDAQ:LNAI) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Sunday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Lunai Bioworks in a research note on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Lunai Bioworks Price Performance

Shares of Lunai Bioworks stock opened at $0.97 on Friday. Lunai Bioworks has a fifty-two week low of $0.81 and a fifty-two week high of $14.00. The company has a market cap of $22.75 million, a P/E ratio of -13.87 and a beta of 0.37. The business has a fifty day moving average price of $1.10.

Lunai Bioworks (NASDAQ:LNAI) last posted its quarterly earnings results on Friday, November 14th. The company reported $0.13 EPS for the quarter.

Hedge Funds Weigh In On Lunai Bioworks

A hedge fund recently bought a new stake in Lunai Bioworks stock. Millennium Management LLC acquired a new position in Lunai Bioworks Inc. (NASDAQ:LNAI) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned about 0.87% of Lunai Bioworks at the end of the most recent reporting period. Institutional investors and hedge funds own 71.41% of the company’s stock.

Lunai Bioworks Company Profile

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.